All In Biotech

Free tool

FAERS Monitor: Multrys

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209376 or its brand name (Multrys, Cupric Sulfate, Manganese Sulfate, Selenious Acid, Zinc Sulfate). Reports on generic versions are filed under their own applications.

Reports

14

Serious

10

71% of reports

Hospitalization

9

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pyrexia4
  • product label confusion3
  • anaemia2
  • diarrhoea2
  • fall2
  • hospitalisation2
  • infection2
  • muscular weakness2
  • pain2
  • physical product label issue2
  • product dose omission issue2
  • vomiting2
  • weight decreased2
  • abdominal discomfort1
  • abdominal pain1

Reports by year received

View as table
YearReports
20213
20222
20231
20241
20267

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,145 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
physical product label issue22531.8700.82,841
product label confusionSignal3773.7283.71,607
muscular weakness226.47.327
infection220.85.821
hospitalisation219.65.419
pyrexiaSignal417.47.647
anaemia215.84.415
weight decreased210.83.09
product dose omission issue210.22.89
fall29.02.57
abdominal discomfort19.01.41
abdominal pain16.51.01
vomiting26.41.85
pain24.91.43
diarrhoea24.71.33

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.